Skip To Main Content
S-B. Kim on Muck Rack

S-B. Kim

As seen in: Annals of Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with S-B.

Contact S-B., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

First-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and tumoral immune cell infiltration data from the phase 2 COLET study

|
By J. A. García-Sáenz, D. W. Miles, S-B. Kim, T. Velu
| Annals of Oncology Verified
Background: Resistance to standard taxane-based chemotherapy is common in TNBC. Preclinical data suggest that MEK inhibition may overcome taxane resistance and enhance antitumor immune response. The safety and efficacy of combining C, a highly selective MEK inhibitor, with P was explored in pts with metastatic/locally advanced TNBC and no prior systemic therapy for metastatic disease. Methods: The COLET study (NCT02322814; EudraCT number, 2014-002230-32) consisted of a safety run-in (n ?
Open in Who Shared Issue with article?
See all 1 articles